Kamboj, G., Sharma, S., Aggarwal, S., Papadopoulos, G., Crowley, S., Rathi, H. (2025)
Pegunigalsidase Alfa (ELFABRIO®) as a Long-term Enzyme Replacement Therapy in Adults with Fabry Disease: A Systematic Literature Review.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: CO178
Barman, P., Gupta, A., Papadopoulos, G., Aristides, M., Rathi, H. (2025)
Cost Effectiveness Analysis of 68Ga-PSMA-11 PET/CT Imaging Followed by 177Lu-PSMA-617 versus Standard of Care in Metastatic Castrate Resistant Prostate Cancer.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: EE161
Kamboj, G., Radotra, A., Barman, P., Aggarwal, S., Papadopoulos, G., Aristides, M., Agresta, B., Rathi, H. (2025)
Prognostic Accuracy and Clinical Effectiveness of 68Ga-PSMA-11 PET/CT (ILLUCCIX®) Imaging Followed by 177Lu-PSMA-617 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Literature Review.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: C0190
Jawla, S., Gaba, U., Gupta, R., Radotra, A. (2025)
Modelling Methods for Economic Evaluations of Non-Statin Lipid Lowering Therapies for Reducing Cardiovascular Risk: A Systematic Literature Review. ISPOR Annual International Meeting 2025. May 13th - 16th, Montreal, QC, Canada, Poster ID: EE91
Barman, P., Shah, M., Kamboj, G., Aggarwal, S., Rathi, H. (2025)
CAR-T Therapy in Asia-Pacific: Is it Reimbursed in your Country?
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: HTA66
Barman, P., Nahan, N., Aggarwal, S., Rathi, H. (2025)
Evolution of Health Technology Assessment (HTA) in India: A Scoping Review and Thematic Analysis.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: HTA140
Barman, P., Kamboj, G., Papadopoulos, G., Aristides, M., Williams, K., Rathi, H. (2025)
Methodological Insights from Recent PBAC Recommendations to Support Biosimilar Reimbursement in Australia.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: HTA232
Barman, P., Gupta, A., Papadopoulos, G., Aristides, M., Rathi, H. (2025)
Budget Impact Analysis of 68Ga-PSMA-11 PET/CT Imaging Followed by 177Lu-PSMA-617 Therapy in Metastatic Castrate Resistant Prostate Cancer.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: EE80
Papadopoulos, G. Barman, P., Gupta, A., Rathi, H. (2025)
Cost-Minimisation and Budget Impact Analysis of NT-proBNP Screening for Systemic Sclerosis-Related Pulmonary Arterial Hypertension in the Australian Healthcare Setting. ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: EE14
Papadopoulos, G. Barman, P., Gupta, A., Rathi, H. (2025)
Cost-Minimisation and Budget-Impact Analysis of NT-proBNP Screening Test for Risk Assessment and Monitoring of Pulmonary Arterial Hypertension (PAH) Patients in the Australian Healthcare Setting.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: EE15
Aggarwal, S., Nahan, N., Kamboj, G., Torelli, F., Empson, V., Serra-Monraba, C., Rathi, H. , Andersen, C., Hasselbalch, H. (2025)
Evaluating the Economic Burden of Polycythemia Vera Across the Disease Continuum: A Systematic Literature Review.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: EE441
Radotra, A., Kamboj, G., Aggarwal, S., Singh, R., Rathi, H. (2025)
Assessing the Accuracy of Artificial Intelligence in Conducting Systematic Literature Reviews. ISPOR Annual International Meeting 2025. May 13th - 16th, Montreal, QC, Canada, Poster ID: MSR111
Kamboj, G., Barman, P., Aggarwal, S, G., Papadopoulos, G., Aristides, M., Agresta, B., Williams, K., Rathi, H. (2025)
Fezolinetant (VEOZA™) as a Non-hormonal Treatment for Moderate-to-Severe Vasomotor Symptoms in Postmenopausal Women: A Systematic Literature Review and Meta-Analysis.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: CO123
Barman, P., Kundu, A., Gupta, A., Aristides, M., Papadopoulos, G., Rathi, H. (2025)
Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations.
ISPOR EUROPE 2025. Nov 09th-12th, Glasgow, Scotland, Poster ID: HPR137
Rathi, H., Malik, A., Behera, D.C., Kamboj, G. (2024)
Assessing GPT-3.5 Turbo’s performance in primary screening across diverse types of systematic literature reviews. Abstracts accepted for the 2nd Global Evidence Summit, Prague, Czech Republic. Cochrane Database of Systematic Reviews 2024; (1 Suppl 1):555.
Kamboj, G., Radotra, A., Barman, P., Dongare, S., Aggarwal, S., Rathi, H. (2024)
Real-World Effectiveness and Safety of First-Line Pembrolizumab Monotherapy for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. ISPOR Annual International Meeting 2024. May 5th - 8th, Atlanta, GA, USA, Poster ID: SA11
Rathi, H., Malik, A., Behera, D.C., Kamboj, G. (2024)
Use of Large Language Model (LLM) for Full-Text Screening in Systematic Literature Reviews: A Comparative Analysis. ISPOR Annual International Meeting 2024. May 5th - 8th, Atlanta, GA, USA, Poster ID: MSR28
Rathi, H., Malik, A., Behera, D.C. (2024)
MSR149 Bridging the Gap Between Theory and Reality in Systematic Literature Reviews Using Artificial Intelligence. Value in Health. 2024 Dec 1;27(12):S467.
Radotra, A., Kamboj, G., Kumar, N., Rathi, H. (2024)
CO174 Evaluating the Impact of Intermittent Fasting on Anthropometric, Cardiovascular, and Metabolic Outcomes: A Targeted Literature Review. Value in Health. 2024 Dec 1;27(12):S47.
Kumar, N., Dongare, S., Aggarwal, S., & Rathi, H. (2024)
Current Clinical Landscape of Alzheimer’s Disease [White Paper]
Kumar, N., Dongare S., Aggarwal, S., Radotra, A., Kamboj, G., Rathi, H. (2024)
SA19 Mapping the Current Clinical Landscape for Alzheimer's Disease: A Qualitative Analysis. ISPOR Annual International Meeting 2024. May 5th - 8th, Atlanta, GA, USA, Poster ID: SA19
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., Jawla, S. (2024)
Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials. Atherosclerosis Plus. 2024 Oct 17.
Barman, P., Kamboj, G., Kumar, N., Rathi, H. (2024)
CO14 Glycaemic Control, Obesity Management, and Cardiovascular Outcomes of Semaglutide for Type 2 Diabetes Mellitus Patients: An Umbrella Review of Meta-Analyses of Randomized Clinical Trials. Value in Health. 2024 Dec 1;27(12):S17-8.
Delaney, C., Agresta, B., Gupta, R., & Papadopoulos, G. (2023)
Budget Impact Analysis Of Utilization Of WavelinQ Endo-arteriovenous Fistula System For Hemodialysis Patients: An Australian Hospital Perspective. Poster presentation at HTAi. June 24th - 28th, Adelaide, Australia, Poster ID: PP103
Gupta, R., Gaba, U., Delaney, C., & Papadopoulos, G. (2023)
Economic Evidence On Hemodialysis Access Creation Procedures In Patients With End-Stage Kidney Disease: A Systematic Literature Review. Oral presentation at HTAi. June 24th - 28th, Adelaide, Australia, Oral Presentation code: OP95
Zhang, J., Wu, Y., Sharma, B., Gupta, R., Jawla, S., Bullimore, MA. (2023)
Epidemiology and Burden of Astigmatism: A Systematic Literature Review. Optom Vis Sci. 2023 Feb 7.
Rathi, H., Malik, A., Behera, D.C., Kamboj, G. (2023)
A Comparative Analysis of Large Language Models (LLM) Utilised in Systematic Literature Review. Podium presentation at ISPOR. November 12th - 15th, Copenhagen, Denmark, Presentation code: P21
Rathi, H., Gaba, U., Delaney, C., Agresta, B., & Papadopoulos, G. (2023)
Budget Impact Analysis of the Introduction of Endo Arteriovenous Fistula System (WAVELINQ) for Hemodialysis Access Creation in Patients with End-Stage Kidney Disease. Poster presented at ISPOR. November 12th - 15th, Copenhagen, Denmark, Poster ID: EE572
Mukhopadhyay, D., Dongare, S., Gupta, R., Rathi H. (2022)
A Systematic Literature Review of the Epidemiology Associated with Human Monkeypox in Children and Adults in India. Poster presented at ISPOR. November 6th -9th, Vienna, Austria, Poster ID: EEH22
Athanasiov, P., Bala, C., Holland, J., Dhariwal, M., Gupta, A., Rathi, H. (2022)
A Cost-effectiveness Analysis of AcrySof IQ Vivity® IOL from Private Health Fund Perspective in Australia
E-Poster presented at 52nd Congress of the RANZCO, 25th Feb. – 1st Mar., Brisbane, Queensland
Papadopoulos, G., Griffin, S., Rathi, H., Gupta, A., Sharma, B., van Bavel, D. (2022)
Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee - an Australian perspective.
E-Poster presented at US-ISPOR, May 15th-18th, Washington, DC, Poster ID: EE338
McCabe, C., Berdahl, J., Dhariwal, M., Gupta, A., Rathi, H. (2022)
A Cost-Benefit Analysis of New Extended Depth of Focus Presbyopia Correcting Intraocular Lens from US Patient Perspective.
Paper presented at ASCRS Annual Meeting. April. 22nd-26th, Washington, DC, Paper ID: 80866
Bala, C., Athanasiov, P., Holland, J., Dhariwal, M., Gupta, A., & Rathi, H. (2022)
A Cost-Effectiveness Analysis of AcrySof IQ Vivity Intraocular Lens (IOL) from Private Health Fund Perspective in Australia Clin Ophthalmol. 2022 Aug 2;16:2403-2412
Berdahl, J., Bala, C., Dhariwal, M., Rathi, H., Gupta, R. (2022)
Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens from the patient's perspective in the United States. PLoS One. 2022 Nov 3;17(11):e0277093.
Athanasiov, P., Bala, C., Holland, J., Dhariwal, M., Gupta, A., Rathi, H. (2022)
A Cost-effectiveness Analysis of AcrySof IQ Vivity® IOL from Private Health Fund Perspective in Australia E-Poster presented at 52nd Congress of the RANZCO, 25th Feb. – 1st Mar., Brisbane, Queensland
Papadopoulos, G., Griffin, S., Rathi, H., Gupta, A., Sharma, B., van Bavel, D. (2022)
Cost-effectiveness analysis of arthroscopic injection of a bioadhesive hydrogel implant in conjunction with microfracture for the treatment of focal chondral defects of the knee - an Australian perspective.
J Med Econ. 2022 Jan-Dec; 25(1): 712– 721.
Gaba, U., Mukhopadhyay, D., Gupta, R., Dongare, S., Rathi, H. (2022)
An Update of Systematic Review of Cost-Utility Studies Conducted from an Indian Perspective. Poster presented at ISPOR. November 6th -9th, Vienna, Austria, Poster ID: EE250
Gupta, R., Sharma, B., Jawla, S., Zhang, J., Wu, Y., Bullimore, M. (2022)
Global Epidemiology, Humanistic Burden, and Economic Burden of Astigmatism: A Systematic Literature Review. Poster presented at ISPOR. November 6th -9th, Vienna, Austria, Poster ID: EPH169
Bala, C., Athanasiov, P., Holland, J., Dhariwal, M., Mills, K., Gupta, A., Rathi, H., O'Boyle, D. (2022)
A Cost-Effectiveness Analysis of Acrysof IQ Vivity Intraocular Lens (IOL) From Private Health Fund Perspective in Australia. Poster presented at ISPOR. November 6th -9th, Vienna, Austria, Poster ID: MT11
Bala, C., Athanasiov, P., Holland, J., Dhariwal, M., Gupta, A., Rathi, H., (2021)
A Cost-effectiveness Analysis of AcrySof IQ Vivity® Intraocular Lens from Private Health Fund Perspective in Australia.
E-Poster presented at 36th APAO Congress, Sept. 05th-11th, Virtual
Berdahl, J., Bala, C., Dhariwal, M., Rathi, H.,Gupta, R. (2021)
A Cost-Benefit Analysis Comparing Trifocal Intraocular Lens (IOL) with Monofocal IOL from Patient Perspective in the USA.
Paper presented at ASCRS ASOA Annual Meeting. July. 23rd-27th 2021, Las Vegas, NV
Rathi, H., Aristides, M., Gupta, A., Crowley, S.,Duff, S., Papadopoulos, G. (2021)
Estimating Incidence Progressed Patients in Partitioned Survival Models - a Comparison of Three Methodologies.
Value in Health, Volume 24, SUPPLEMENT 1, S174
McCabe, C., Berdahl, J., Dhariwal, M., Gupta, A., Rathi, H. (2021)
Quality of life with bilateral implantation of a new extended depth of focus (EDF) intraocular lens (IOL).
E-Poster presented at AAO, Nov. 12th-15th, Virtual/New Orleans, LA, Poster ID: PO127
Bala, C., Athanasiov, P., Holland, J., Dhariwal, M., Gupta, A., Rathi, H. (2021)
A Cost-effectiveness Analysis of AcrySof IQ Vivity® IOL from Private Health Fund Perspective in Australia.
E-Poster presented at 39th Congress of the ESCRS, Oct. 08th-11th, Amsterdam
Khurana, T., Gupta, A., Rathi, H. (2021)
The state of cost-utility analysis in India: A systematic review
Perspect Clin Res. 2021 Oct-Dec; 12(4): 179–183.
Bala, C., Berdahl, J., Dhariwal, M., Rathi, H., Gupta, R. (2021)
A Cost-benefit Analysis of AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) from Patient Perspective in the USA.
E-Poster presented at 39th Congress of the ESCRS, Oct. 08th-11th, Amsterdam
Khurana, T., Gupta, A., Rathi, H. (2020)
A Systematic Review of Cost Utility Studies Conducted from an Indian Perspective.
Value in Health Regional Issues, Volume 22, S81
Khurana, T., Gupta, A., Rathi, H. (2020)
An Analysis of Utility Values USED in Cost Utility Studies Conducted from an Indian Perspective.
Value in Health Regional Issues, Volume 22, S81 - S82
Sharan, N., Rathi, H. (2019)
Quality of Life of Individuals with Electromagnetic Hypersensitivity- A Targeted Review of Literature.
Value in Health, 22 (SUPPL2), S348.
Sharan, N., Rathi, H. (2019)
Efficacy and Safety of Lonafarnib For the Treatment of Progeria- A Qualitative Systematic Review of Literature.
Value in Health, 22 (SUPPL2), S335–S336.
Lynch, K., Aristides, M., Rathi, H., Papadopoulos, G., & McGuire, A. (2018)
Cost analysis of an intranasal naloxone take-home program: an Australian case study.
In Drug and Alcohol Review, 37(S3), pp. S48-S48).
Rathi, H., Pennington, B., Amadi, A., Lister, S., Nanuwa, K. (2015)
The Efficacy and Safety of Abatacept, Adalimumab, Etanercept And Tocilizumab are Comparable In Polyarticular Juvenile Idiopathic Arthritis [abstract].
Value in Health, 18 (7), A636.
Jain, M., Sonathi, V., Rathi, H., Thomas, S.K., & Mollon, P. (2014)
The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective [abstract].
Value in Health, 17 (7), A483-A484.
Jain, M., Sonathi, V., Rathi, H., Bakuli, A., Thomas, S.K., & Mollon, P. (2014)
A DE-NOVO Model to Predict Outcomes of a New Hypothetical Intervention to Reduce CV Risk in Post Mi Patients [abstract].
Value in Health, 17 (7), A558.
Malcolm, W. A., Leteneux, C., Claxton, L., Taylor, M., & Rathi, H. (2013)
The Budget Impact of Introducing Ranibizumab in England and Wales for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia [abstract].
Value Health, 16 (7), A503.
Bergvall, N., Rathi, H., Nixon, R. M., Thom, H. H. Z. (2013)
Efficacy of Fingolimod in Delaying Confirmed Disability Progression in Patients Failing Prior Treatment: A Markov Model Application to Estimate Time to Disability Health States [abstract].
Value Health, 16 (7), A618.
Bergvall, N., Rathi, H., Nixon, R. M., Thom, H. H. Z., Alsop, J., Dunsire, L. (2013)
Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression [abstract].
Value Health, 16 (7), A619.
Leteneux, C., Claxton, L., Malcolm, W. A., Taylor, M., & Rathi, H. (2013)
Cost-Effectiveness of Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia in the United Kingdom [abstract].
Value Health, 16 (7), A505.
